Galecto Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
/ 
Frequently asked questions
To buy Galecto Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Galecto Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Galecto Inc. is GLTO:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Galecto Inc. has its primary listing on NASDAQ. You can trade Galecto Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Galecto Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Galecto Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Galecto Inc..